Want to see IDYA full AI Analyst Report?
Top Page
IDEAYA Biosciences
(NASDAQ:IDYA)
Select Model
Select Model
Rating:65Neutral
Price Target:
$37.00
▲(9.11% Upside)
Action:Reiterated
Date:06/24/26
The score is driven primarily by improving but still loss-making financials (strong revenue/gross margin and low leverage, but continued operating losses and cash burn). Technicals add support with price above key moving averages and positive MACD. Valuation remains a constraint due to negative earnings and no dividend yield. Recent corporate events are a positive catalyst, led by strengthened financing and favorable clinical/regulatory updates.
Positive Factors
Strong balance sheet / recent capital raise
A $323.6M equity raise materially strengthens liquidity and extends runway for R&D-heavy programs. Combined with historically low leverage, this funding reduces near-term financing pressure, enabling multi-year clinical development and strategic collaborations without immediate cash constraints.
Negative Factors
Persistent operating losses and negative cash flow
IDEAYA remains loss-making with sizeable negative operating and free cash flow, requiring continued funding to support trials. While cash burn improved versus 2024, persistent negative cash generation means financing risk and potential dilution remain structural until products generate operating cash flow.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong balance sheet / recent capital raise
A $323.6M equity raise materially strengthens liquidity and extends runway for R&D-heavy programs. Combined with historically low leverage, this funding reduces near-term financing pressure, enabling multi-year clinical development and strategic collaborations without immediate cash constraints.
Read all positive factors
IDEAYA Biosciences (IDYA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$3.58B
Dividend YieldN/A
Average Volume (3M)1.08M
Price to Earnings (P/E)―
Beta (1Y)1.28
Revenue Growth3118.14%
EPS Growth55.95%
CountryUS
Employees131
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.58
Shares Outstanding95,083,145
10 Day Avg. Volume1,644,630
30 Day Avg. Volume1,077,560
Financial Highlights & Ratios
PEG Ratio0.44
Price to Book (P/B)2.99
Price to Sales (P/S)13.99
P/FCF Ratio-41.64
Enterprise Value/Market Cap0.79
Enterprise Value/Revenue12.56
Enterprise Value/Gross Profit42.27
Enterprise Value/Ebitda-20.88
Forecast
1Y Price Target
$54.20Price Target Upside59.83% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
EPS Forecast (FY)-4.32
Revenue Forecast (FY)$35.41M
IDEAYA Biosciences Business Overview & Revenue Model
Company Description
IDEAYA Biosciences, Inc. is a precision oncology company primarily dedicated to identifying and advancing targeted therapies, particularly leveraging the concept of synthetic lethality. The firm aims to develop specific treatments for patient grou...
How the Company Makes Money
IDEAYA Biosciences primarily makes money through collaboration and partnership revenue rather than product sales, as it is a clinical-stage company without marketed therapeutics (null if this status changes). Key revenue streams include (1) upfron...
IDEAYA Biosciences Financial Statement Overview
Summary
Income Statement
34
Negative
Balance Sheet
78
Positive
Cash Flow
43
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 225.27M | 218.71M | 7.00M | 23.39M | 50.93M | 27.94M |
| Gross Profit | 66.91M | 214.12M | 3.17M | 19.38M | 48.83M | 26.22M |
| EBITDA | -135.46M | -109.11M | -270.64M | -108.95M | -56.55M | -48.04M |
| Net Income | -140.06M | -113.70M | -274.48M | -112.96M | -58.66M | -49.76M |
Balance Sheet | ||||||
| Total Assets | 1.03B | 1.11B | 1.12B | 649.32M | 387.97M | 381.35M |
| Cash, Cash Equivalents and Short-Term Investments | 671.20M | 639.39M | 676.32M | 525.11M | 364.83M | 246.77M |
| Total Debt | 28.60M | 27.91M | 19.17M | 2.87M | 3.48M | 5.18M |
| Total Liabilities | 93.08M | 86.39M | 64.94M | 28.23M | 38.51M | 79.83M |
| Stockholders Equity | 937.27M | 1.02B | 1.06B | 621.09M | 349.45M | 301.51M |
Cash Flow | ||||||
| Free Cash Flow | -87.93M | -73.47M | -251.44M | -117.59M | -90.62M | -58.42M |
| Operating Cash Flow | -85.93M | -71.10M | -247.58M | -115.22M | -87.17M | -55.78M |
| Investing Cash Flow | 109.11M | 69.98M | -502.56M | -158.46M | -33.40M | -69.67M |
| Financing Cash Flow | 4.82M | 29.78M | 677.55M | 362.72M | 97.17M | 145.45M |
IDEAYA Biosciences Technical Analysis
Positive
33.91
Price Trends
30.43
Positive
31.44
Positive
31.72
Positive
Market Momentum
2.10
Negative
71.23
Negative
84.05
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IDYA, the sentiment is Positive. The current price of 33.91 is above the 20-day moving average (MA) of 32.59, above the 50-day MA of 30.43, and above the 200-day MA of 31.72, indicating a bullish trend. The MACD of 2.10 indicates Negative momentum. The RSI at 71.23 is Negative, neither overbought nor oversold. The STOCH value of 84.05 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IDYA.
IDEAYA Biosciences Risk Analysis
IDEAYA Biosciences disclosed 76 risk factors in its most recent earnings report. IDEAYA Biosciences reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
IDEAYA Biosciences Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
68 Neutral | $3.23B | -1,344.27 | -1.41% | ― | 95.29% | 98.21% | |
65 Neutral | $3.58B | -23.83 | -13.96% | ― | 3118.14% | 55.95% | |
61 Neutral | $2.23B | -5.18 | -34.11% | ― | 78.34% | -161.91% | |
59 Neutral | $5.29B | -116.16 | -26.79% | ― | 96.03% | 82.27% | |
55 Neutral | $5.26B | -27.75 | -244.61% | ― | ― | -28.74% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $3.58B | -54.36 | -5.89% | ― | 157.97% | 86.11% |
* Healthcare Sector Average
IDYA
IDEAYA Biosciences
37.65
16.49
77.93%
AGIO
Agios Pharma
37.58
2.37
6.73%
TVTX
Travere Therapeutics
56.92
42.32
289.86%
CELC
Celcuity
107.95
94.61
709.22%
ARQT
Arcutis Biotherapeutics
25.81
12.42
92.76%
BEAM
Beam Therapeutics
34.79
15.61
81.39%
IDEAYA Biosciences Corporate Events
Business Operations and StrategyExecutive/Board ChangesShareholder Meetings
IDEAYA Biosciences Shareholders Back Leadership, Governance Changes
Positive
Jun 23, 2026
On June 16, 2026, IDEAYA Biosciences, Inc. held its 2026 Annual Meeting of Stockholders, where investors voted on the election of three Class I directors, ratification of the company’s independent auditor for the 2026 fiscal year, and a non-...
Business Operations and StrategyPrivate Placements and Financing
IDEAYA Biosciences Raises $324 Million in Equity Offering
Positive
Jun 10, 2026
On June 8, 2026, IDEAYA Biosciences entered into an underwriting agreement with a syndicate of investment banks to sell 5,555,556 shares of common stock and pre-funded warrants for 5,555,576 additional shares, with public pricing set at $27.00 per...
Business Operations and StrategyProduct-Related Announcements
IDEAYA, Roche launch PRMT5 and pan-RAS collaboration
Positive
Jun 3, 2026
On June 3, 2026, IDEAYA Biosciences announced a clinical collaboration with Roche to test IDEAYA’s investigational PRMT5 inhibitor IDE892 with Roche’s pan-RAS inhibitor RG6505 in patients with MTAP-deleted, RAS-mutant pancreatic ductal...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
IDEAYA Highlights Positive Phase 2/3 Darovasertib Trial Results
Positive
Jun 1, 2026
On June 1, 2026, IDEAYA Biosciences and Servier presented complete primary analysis data from the global Phase 2/3 registrational OptimUM-02 trial of darovasertib plus crizotinib in first-line HLA*A2:01 negative metastatic uveal melanoma at the AS...
Private Placements and FinancingRegulatory Filings and Compliance
IDEAYA Biosciences Files New Shelf Registration Statement
Neutral
May 5, 2026
On May 5, 2026, IDEAYA Biosciences filed a new automatic shelf registration statement on Form S-3ASR with the SEC to replace its prior shelf registration that was set to expire on June 26, 2026, effectively terminating the older registration under...
Business Operations and StrategyProduct-Related Announcements
IDEAYA, AstraZeneca launch global IDE849-Imfinzi lung cancer trial
Positive
Apr 9, 2026
On April 8, 2026, IDEAYA Biosciences entered a clinical collaboration with AstraZeneca to test IDE849, its investigational DLL3 TOP1 antibody-drug conjugate, in combination with AstraZeneca’s PD-L1 inhibitor Imfinzi in extensive-stage small ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.